Prevalence of human papillomavirus infection in unselected surepath samples using the APTIMA HPV mRNA assay

Journal of Molecular Diagnostics

Volumn 15, Issue 5, 2013, Pages 670-677

  Rebolj, Matejka ^a   Preisler, Sarah ^b   Ejegod, Ditte M ^b   Bonde, Jesper ^b   Rygaard, Carsten ^b   Lynge, Elsebeth ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PROTEIN E6; PROTEIN E7;

ADOLESCENT; ADULT; AGED; ARTICLE; ASSAY; CONTROLLED STUDY; CYTOLOGY; FEMALE; GENOTYPE; HIGH RISK POPULATION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; NONHUMAN; PAPILLOMAVIRUS INFECTION; PROTEIN DETERMINATION; SCREENING TEST; UTERINE CERVIX CYTOLOGY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; MOLECULAR TYPING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; REAGENT KITS, DIAGNOSTIC; REPRODUCIBILITY OF RESULTS; RNA, MESSENGER; RNA, VIRAL; YOUNG ADULT;

EID: 84882249350     PISSN: 15251578     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmoldx.2013.04.002     Document Type: Article

References (28)

1. G. Ronco, P. Giorgi-Rossi, F. Carozzi, M. Confortini, P. Dalla Palma, A. Del Mistro, B. Ghiringhello, S. Girlando, A. Gillio-Tos, L. De Marco, C. Naldoni, P. Pierotti, R. Rizzolo, P. Schincaglia, M. Zorzi, M. Zappa, N. Segnan, and J. Cuzick Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial Lancet Oncol 11 2010 249 257
2. D.C. Rijkaart, J. Berkhof, L. Rozendaal, F.J. van Kemenade, N.W. Bulkmans, D.A. Heideman, G.G. Kenter, J. Cuzick, P.J. Snijders, and C.J. Meijer Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial Lancet Oncol 13 2012 78 88
3. M. Rebolj, I. Pribac, and E. Lynge False-positive human papillomavirus DNA tests in cervical screening: it is all in a definition Eur J Cancer 47 2011 255 261
4. J. Doorbar Molecular biology of human papillomavirus infection and cervical cancer Clin Sci (Lond) 110 2006 525 541
5. K. Cuschieri, and N. Wentzensen Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia Cancer Epidemiol Biomarkers Prev 17 2008 2536 2545
6. V. Bouvard, R. Baan, K. Straif, Y. Grosse, B. Secretan, F. El Ghissassi, L. Ibrahim-Tallaa, N. Guha, C. Freeman, L. Galichet, and V. Cogliano A review of human carcinogens-part B: biological agents Lancet Oncol 10 2009 321 322
7. A. Szarewski, L. Ambroisine, L. Cadman, J. Austin, L. Ho, G. Terry, S. Liddle, R. Dina, J. McCarthy, H. Buckley, C. Bergeron, P. Soutter, D. Lyons, and J. Cuzick Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears Cancer Epidemiol Biomarkers Prev 17 2008 3033 3042
8. M. Waldstrom, and D. Ornskov Comparison of the clinical performance of an HPV mRNA test and an HPV DNA test in triage of atypical squamous cells of undetermined significance (ASC-US) Cytopathology 23 2012 389 395
9. I.T. Ovestad, U. Vennestrom, L. Andersen, E. Gudlaugsson, A.C. Munk, A. Malpica, W. Feng, F. Voorhorst, E.A. Janssen, and J.P. Baak Comparison of different commercial methods for HPV detection in follow-up cytology after ASCUS/LSIL, prediction of CIN2-3 in follow up biopsies and spontaneous regression of CIN2-3 Gynecol Oncol 123 2011 278 283
10. J. Dockter, A. Schroder, C. Hill, L. Guzenski, J. Monsonego, and C. Giachetti Clinical performance of the APTIMA HPV Assay for the detection of high-risk HPV and high-grade cervical lesions J Clin Virol 45 Suppl 1 2009 S55 S61
11. J. Monsonego, M.G. Hudgens, L. Zerat, J.C. Zerat, K. Syrjanen, P. Halfon, F. Ruiz, and J.S. Smith Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: the FASE study Int J Cancer 129 2010 691 701
12. S. Ratnam, F. Coutlee, D. Fontaine, J. Bentley, N. Escott, P. Ghatage, V. Gadag, G. Holloway, E. Bartellas, N. Kum, C. Giede, and A. Lear Aptima HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 Assay but more specific at detecting cervical precancer and cancer J Clin Microbiol 49 2011 557 564
13. A. Clad, M. Reuschenbach, J. Weinschenk, R. Grote, J. Rahmsdorf, and N. Freudenberg Performance of the APTIMA high-risk HPV mRNA assay in a referral population in comparison with Hybrid Capture 2 and cytology J Clin Microbiol 49 2011 1071 1076
14. R. Wu, S.E. Belinson, H. Du, W. Na, X. Qu, R. Wu, Y. Liu, C. Wang, Y. Zhou, L. Zhang, and J.L. Belinson Human papillomavirus messenger RNA assay for cervical cancer screening: the Shenzhen Cervical Cancer Screening Trial I Int J Gynecol Cancer 20 2010 1411 1414
15. M. Reuschenbach, A. Clad, D.C. von Knebel, N. Wentzensen, J. Rahmsdorf, F. Schaffrath, H. Griesser, N. Freudenberg, and D.M. von Knebel Performance of p16INK4a-cytology. HPV mRNA, and HPV DNA testing to identify high grade cervical dysplasia in women with abnormal screening results Gynecol Oncol 119 2010 98 105
16. M. Arbyn, J. Roelens, K. Cuschieri, J. Cuzick, A. Szarewski, S. Ratnam, M. Reuschenbach, S. Belinson, J.L. Belinson, and J. Monsonego The APTIMA HPV assay versus the hybrid capture 2 test in triage of women with ASC-USor LSIL cervical cytology: a meta-analysisof the diagnostic accuracy Int J Cancer 132 2013 101 108
17. C.A. Horvath, G. Boulet, S. Sahebali, C. Depuydt, T. Vermeulen, D. van den Broeck, A. Vereecken, and J. Bogers Effects of fixation on RNA integrity in a liquid-based cervical cytology setting J Clin Pathol 61 2008 132 137
18. N. Powell, K. Smith, and A. Fiander Recovery of human papillomavirus nucleic acids from liquid-based cytology media J Virol Methods 137 2006 58 62
19. P.G. Murphy, D.T. Henderson, M.D. Adams, E.A. Horlick, E.P. Dixon, L.M. King, P.L. Avissar, C.A. Brown, T.J. Fischer, and D.P. Malinowski Isolation of RNA from cell lines and cervical cytology specimens stored in BD SurePath preservative fluid and downstream detection of housekeeping gene and HPV E6 expression using real time RT-PCR J Virol Methods 156 2009 138 144
20. M. Waldstrom, and D. Ornskov Clinical performance of a human papillomavirus messenger RNA test (Aptima HPV Assay) on residual material from archived 3-year-old PreservCyt samples with low-grade squamous intraepithelial lesion Arch Pathol Lab Med 135 2011 1052 1056
21. J. Clemmesen, and A. Nielsen The social distribution of cancer in Copenhagen, 1943 to 1947 Br J Cancer 5 1951 159 171
22. S.K. Kjaer, G. Breugelmans, C. Munk, J. Junge, M. Watson, and T. Iftner Population-based prevalence, type- and age-specific distribution of HPV in women before introduction of an HPV-vaccination program in Denmark Int J Cancer 123 2008 1864 1870
23. Styregruppen for DKLS: Årsrapport DKLS 2011: Dansk Kvalitetsdatabase for Livmoderhalskræftscreening [annual report 2011: Danish Quality Assurance database for cervical cancer screening]. Hvidovre, DKLS, 2012, pp 1-122
24. C.J. Meijer, J. Berkhof, P.E. Castle, A.T. Hesselink, E.L. Franco, G. Ronco, M. Arbyn, F.X. Bosch, J. Cuzick, J. Dillner, D.A. Heideman, and P.J. Snijders Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older Int J Cancer 124 2009 516 520
25. B. Bjerregaard, and O.B. Larsen The Danish Pathology Register Scand J Public Health 39 2011 72 74
26. A. Szarewski, D. Mesher, L. Cadman, J. Austin, L. Ashdown-Barr, L. Ho, G. Terry, S. Liddle, M. Young, M. Stoler, J. McCarthy, C. Wright, C. Bergeron, W.P. Soutter, D. Lyons, and J. Cuzick Comparison of seven tests for high-grade cervical intraepithelial neoplasia in women with abnormal smears: the predictors 2 study J Clin Microbiol 50 2012 1867 1873
27. P.E. Castle Screening: hPV testing for cervical cancer: the good, the bad, and the ugly Nat Rev Clin Oncol 7 2010 364 365
28. J. Cuzick, M. Arbyn, R. Sankaranarayanan, V. Tsu, G. Ronco, M.H. Mayrand, J. Dillner, and C.J. Meijer Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries Vaccine 26 Suppl 10 2008 K29 K41